
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is transitioning from serving consumer markets to enterprise ones and may see share gains and earnings revisions. The company's strong results in the first quarter and potential contract with a new hospital system channel partner suggest it is on track to meet its goals. However, there are potential risks associated with the HCIT space, including government program cuts and price competition, which could impact DarioHealth's growth prospects.
Bears say
DarioHealth is currently operating at a loss due to inconsistent revenue growth and a shift away from one-time pharmaceutical revenue. While the company has shown efficiency in managing expenses, it will still be difficult to scale without a clear path to profitability. The recent partnerships and potential new channel partners may provide a boost, but the company will need to demonstrate clearer evidence of revenue acceleration before seeing a significant increase in stock value.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares